EV/EBITDA

With an EV/EBITDA of 8.8x, Enterprise Value relative to Earnings Before Interest, Taxes, Depreciation, and Amortization measures how many years of pre-debt, pre-tax operating profit would be needed to buy the entire company.

This is well below the healthcare sector median of 13.1x, placing Biogen in the 28th percentile among its peers — meaning it is cheaper than most comparable healthcare stocks based on this profitability multiple. Trend data is unavailable: the year-over-year change, quarter-over-quarter change, and last eight quarters are all listed as N/A, and only a single historical value of 8.8x is provided. Without a trend, it is impossible to assess whether this low multiple reflects persistent undervaluation or a recent drop that could signal deteriorating fundamentals. The low level alone suggests limited downside risk relative to the sector, but the absence of trend information introduces ambiguity. This metric supports the overall NEUTRAL verdict because a cheap valuation is not enough to recommend buying when no directional context exists to confirm stability or improvement.

Frequently Asked Questions

Closest Sector Peers